Predicting survival after irradiation of metastases from pancreatic cancer

Louisa Bolm, Stefan Janssen, Lukas Käsmann, Ulrich Wellner, Tobias Bartscht, Steven E. Schild, Dirk Rades

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background/Aim: Patients with metastases from pancreas cancer benefit from individualized care, including radiotherapy for symptom control. To administer the optimal radiation therapy, it is important to understand a patient's prognosis. Patients and Methods: Seven variables were analyzed regarding their relationship with survival: age, gender, Karnofsky performance score (KPS), number of metastatic sites, interval from diagnosis of pancreatic cancer to irradiation of metastases, type of irradiated metastasis, and radiation dose. Results: On univariate analysis, survival was positively associated with age ≤67 years (p=0.045), KPS >70 (p<0.001), and involvement of only one metastatic site (p=0.013). A longer interval between diagnosis and irradiation of metastases showed a trend for better survival (p=0.077). On multivariate analysis, age [risk ratio (RR)=4.29; p=0.004], KPS (RR=1.95; p=0.020), number of metastatic sites (RR=2.20; p=0.009) and interval to irradiation (RR=4.41; p=0.005) achieved significance. Conclusion: The present study identified four independent predictors of survival in patients with pancreatic cancer irradiated for metastasis and thus contributes to treatment optimization.

Original languageEnglish (US)
Pages (from-to)4105-4108
Number of pages4
JournalAnticancer Research
Volume35
Issue number7
StatePublished - Jul 1 2015

Fingerprint

Pancreatic Neoplasms
Neoplasm Metastasis
Odds Ratio
Survival
Radiotherapy
Survival Analysis
Multivariate Analysis
Radiation
Therapeutics

Keywords

  • Expected survival
  • Irradiation
  • Metastasis
  • Pancreatic cancer
  • Predictive factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bolm, L., Janssen, S., Käsmann, L., Wellner, U., Bartscht, T., Schild, S. E., & Rades, D. (2015). Predicting survival after irradiation of metastases from pancreatic cancer. Anticancer Research, 35(7), 4105-4108.

Predicting survival after irradiation of metastases from pancreatic cancer. / Bolm, Louisa; Janssen, Stefan; Käsmann, Lukas; Wellner, Ulrich; Bartscht, Tobias; Schild, Steven E.; Rades, Dirk.

In: Anticancer Research, Vol. 35, No. 7, 01.07.2015, p. 4105-4108.

Research output: Contribution to journalArticle

Bolm, L, Janssen, S, Käsmann, L, Wellner, U, Bartscht, T, Schild, SE & Rades, D 2015, 'Predicting survival after irradiation of metastases from pancreatic cancer', Anticancer Research, vol. 35, no. 7, pp. 4105-4108.
Bolm L, Janssen S, Käsmann L, Wellner U, Bartscht T, Schild SE et al. Predicting survival after irradiation of metastases from pancreatic cancer. Anticancer Research. 2015 Jul 1;35(7):4105-4108.
Bolm, Louisa ; Janssen, Stefan ; Käsmann, Lukas ; Wellner, Ulrich ; Bartscht, Tobias ; Schild, Steven E. ; Rades, Dirk. / Predicting survival after irradiation of metastases from pancreatic cancer. In: Anticancer Research. 2015 ; Vol. 35, No. 7. pp. 4105-4108.
@article{fb5824c29bee4722be691b9388d650a5,
title = "Predicting survival after irradiation of metastases from pancreatic cancer",
abstract = "Background/Aim: Patients with metastases from pancreas cancer benefit from individualized care, including radiotherapy for symptom control. To administer the optimal radiation therapy, it is important to understand a patient's prognosis. Patients and Methods: Seven variables were analyzed regarding their relationship with survival: age, gender, Karnofsky performance score (KPS), number of metastatic sites, interval from diagnosis of pancreatic cancer to irradiation of metastases, type of irradiated metastasis, and radiation dose. Results: On univariate analysis, survival was positively associated with age ≤67 years (p=0.045), KPS >70 (p<0.001), and involvement of only one metastatic site (p=0.013). A longer interval between diagnosis and irradiation of metastases showed a trend for better survival (p=0.077). On multivariate analysis, age [risk ratio (RR)=4.29; p=0.004], KPS (RR=1.95; p=0.020), number of metastatic sites (RR=2.20; p=0.009) and interval to irradiation (RR=4.41; p=0.005) achieved significance. Conclusion: The present study identified four independent predictors of survival in patients with pancreatic cancer irradiated for metastasis and thus contributes to treatment optimization.",
keywords = "Expected survival, Irradiation, Metastasis, Pancreatic cancer, Predictive factors",
author = "Louisa Bolm and Stefan Janssen and Lukas K{\"a}smann and Ulrich Wellner and Tobias Bartscht and Schild, {Steven E.} and Dirk Rades",
year = "2015",
month = "7",
day = "1",
language = "English (US)",
volume = "35",
pages = "4105--4108",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - Predicting survival after irradiation of metastases from pancreatic cancer

AU - Bolm, Louisa

AU - Janssen, Stefan

AU - Käsmann, Lukas

AU - Wellner, Ulrich

AU - Bartscht, Tobias

AU - Schild, Steven E.

AU - Rades, Dirk

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background/Aim: Patients with metastases from pancreas cancer benefit from individualized care, including radiotherapy for symptom control. To administer the optimal radiation therapy, it is important to understand a patient's prognosis. Patients and Methods: Seven variables were analyzed regarding their relationship with survival: age, gender, Karnofsky performance score (KPS), number of metastatic sites, interval from diagnosis of pancreatic cancer to irradiation of metastases, type of irradiated metastasis, and radiation dose. Results: On univariate analysis, survival was positively associated with age ≤67 years (p=0.045), KPS >70 (p<0.001), and involvement of only one metastatic site (p=0.013). A longer interval between diagnosis and irradiation of metastases showed a trend for better survival (p=0.077). On multivariate analysis, age [risk ratio (RR)=4.29; p=0.004], KPS (RR=1.95; p=0.020), number of metastatic sites (RR=2.20; p=0.009) and interval to irradiation (RR=4.41; p=0.005) achieved significance. Conclusion: The present study identified four independent predictors of survival in patients with pancreatic cancer irradiated for metastasis and thus contributes to treatment optimization.

AB - Background/Aim: Patients with metastases from pancreas cancer benefit from individualized care, including radiotherapy for symptom control. To administer the optimal radiation therapy, it is important to understand a patient's prognosis. Patients and Methods: Seven variables were analyzed regarding their relationship with survival: age, gender, Karnofsky performance score (KPS), number of metastatic sites, interval from diagnosis of pancreatic cancer to irradiation of metastases, type of irradiated metastasis, and radiation dose. Results: On univariate analysis, survival was positively associated with age ≤67 years (p=0.045), KPS >70 (p<0.001), and involvement of only one metastatic site (p=0.013). A longer interval between diagnosis and irradiation of metastases showed a trend for better survival (p=0.077). On multivariate analysis, age [risk ratio (RR)=4.29; p=0.004], KPS (RR=1.95; p=0.020), number of metastatic sites (RR=2.20; p=0.009) and interval to irradiation (RR=4.41; p=0.005) achieved significance. Conclusion: The present study identified four independent predictors of survival in patients with pancreatic cancer irradiated for metastasis and thus contributes to treatment optimization.

KW - Expected survival

KW - Irradiation

KW - Metastasis

KW - Pancreatic cancer

KW - Predictive factors

UR - http://www.scopus.com/inward/record.url?scp=84937156706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937156706&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 4105

EP - 4108

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -